ライフサイエンスコーパス: multicenter trial

1 ese results need validation in a prospective multicenter trial.

2 urposes were prospectively recruited in this multicenter trial.

3 600 mg daily) or placebo in a double-blind, multicenter trial.

4 gastrointestinal malignancies in a previous multicenter trial.

5 RST) was a phase II, randomized, open-label, multicenter trial.

6 ality after allogeneic MRD HCT in a phase 3, multicenter trial.

7 ADIAL or femoral approach) was a randomized, multicenter trial.

8 randomized controlled, parallel, superiority multicenter trial.

9 rvastatin 10 versus 80 mg in a double-blind, multicenter trial.

10 ith CR was observed in this large randomized multicenter trial.

11 placebo in a 3-year phase III, double-blind, multicenter trial.

12 mised controlled, parallel-group superiority multicenter trial.

13 symptomatic patients were determined in this multicenter trial.

14 sk patients needs to be confirmed in a large multicenter trial.

15 ted seizure, recently completed a successful multicenter trial.

16 l function can be assessed by telephone in a multicenter trial.

17 1 week in a prospective, placebo-controlled, multicenter trial.

18 plus standard care (n = 77) in an open-label multicenter trial.

19 m positive blood cultures was evaluated in a multicenter trial.

20 andomized, double-blind, placebo-controlled, multicenter trial.

21 ow-up, 27.4 months) in a prospective phase 2 multicenter trial.

22 for the detection of MI in an international, multicenter trial.

23 Randomized controlled double-blinded multicenter trial.

24 ith glioblastoma who were participating in a multicenter trial.

25 ks of sitagliptin 100 mg/day vs placebo in a multicenter trial.

26 luid strategy should be explored in a larger multicenter trial.

27 were included in our double-blind phase III multicenter trial.

28 om retinal vein occlusion, also confirmed in multicenter trials.

29 DME and have been confirmed by several large multicenter trials.

30 )F-FDG signal was evaluated in 2 prospective multicenter trials.

31 ive symptoms and call for adequately powered multicenter trials.

32 in a relatively short time period in several multicenter trials.

33 probes can be used based on availability in multicenter trials.

34 ted to facilitate the use of central IRBs in multicenter trials.

35 bservations have not been validated in large multicenter trials.

36 ted catheters need to be assessed via large, multicenter trials.

37 t to be validated in prospective randomized, multicenter trials.

38 d as a problem that limits the use of PET in multicenter trials.

39 well as clinically meaningful end points for multicenter trials.

40 and able to report their symptomatic AEs in multicenter trials.

41 leukemia is leading to expanded use through multicenter trials.

42 it is feasible to implement this approach in multicenter trials.

43 an issue in routine clinical processes or in multicenter trials.

44 141 mCRC patients included in a prospective multicenter trial, 132 were evaluable for OS/PFS.

45 , SETTING, AND PATIENTS: Randomized clinical multicenter trial (14 centers in 6 countries) between Ma

46 METHODS AND In this prospective, multicenter trial, 169 patients underwent FFR assessment

47 In this phase III multicenter trial, 307 patients with OC were randomly as

48 In a prospective, nonrandomized multicenter trial, 45 eligible patients received rituxim

49 In a randomized, prospective, open-label, multicenter trial, 48 patients with severe CS complicati

50 In this multicenter trial, 692 overweight/obese women who were,

51 -small cell lung cancer from the prospective multicenter trials ACRIN 6678 (n = 34) and MK-0646-008 (

52 onary syndrome (n=48 282) were enrolled in a multicenter trial across 10 hospitals in Scotland.

53 This open, randomized, multicenter trial aimed to assess the efficacy and safet

54 f 1,741 patients with sepsis enrolled in the multicenter trial ALBIOS (Albumin Italian Outcome Sepsis

55 ND PARTICIPANTS: A double-blind, randomized, multicenter trial (Aliskiren Quantitative Atherosclerosi

56 In this randomized controlled, multicenter trial, all patients >= 18 years with a singl

57 prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of

58 We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface a

59 outcomes of these patients in a prospective multicenter trial and investigated whether they develope

60 nced disease were enrolled in this phase II, multicenter trial and randomly assigned to receive afati

61 e stage IIIA NSCLC were enrolled to a German multicenter trial and randomly assigned to receive eithe

62 anced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to re

63 Only a few methods have progressed to multicenter trials and even fewer have become part of cl

64 This trial should be followed by pragmatic multicenter trials and international registries.

65 treatment strategies, various institutions, multicenter trials, and cooperative groups by allowing f

66 Pharmacogenetic studies can be conducted in multicenter trials, and our findings demonstrate that wi

67 Although large, prospective, multicenter trials are lacking, certain factors such as

68 es of neuropsychological function for use in multicenter trials are lacking.

69 However, multicenter trials are needed to determine if those find

70 apeutic options in well-designed prospective multicenter trials are needed to identify the most effec

71 Large prospective, multicenter trials are now needed to validate the new in

72 Multicenter trials are required with close monitoring of

73 This 3-year, prospective, multicenter trial assessed the safety and efficacy of de

74 A double-blind, randomized, multicenter trial at 362 academic and community hospital

75 AND PARTICIPANTS: Double-blind, randomized, multicenter trial at 97 academic and community hospitals

76 This prospective randomized multicenter trial block randomized patients to a restric

77 CE-SSFP and T2-STIR data from 2 recent multicenter trials, CHILL-MI and MITOCARE (n=215), were

78 In this phase II multicenter trial (ClinicalTrials.gov identifier: NCT031

79 This multicenter trial compared 1.0% prednisolone sodium phos

80 The present multicenter trial compared 12 weeks of supervised interv

81 This phase 3 randomized, open-label, multicenter trial compared inolimomab vs usual care in a

82 This prospective, randomized, multicenter trial compared primary nitinol stent placeme

83 This double-blind, multicenter trial compared the efficacy and safety of a

84 We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with

85 GN Randomized, controlled, observer-blinded, multicenter trial comparing mechlorethamine, 0.02%, gel

86 p trial Z0011 was a prospective, randomized, multicenter trial comparing overall survival between pat

87 This first multicenter trial comparing propofol with sevoflurane an

88 ious and nondelirious patients enrolled in a multicenter trial comparing protocolized sedation with p

89 d Tomography Angiography Using 64 Detectors) multicenter trial comparing the diagnostic performance o

90 ent Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and vorico

91 In the absence of large randomized multicenter trials comparing the use of intermittent pne

92 ING, AND PARTICIPANTS: Two-year, randomized, multicenter trial conducted at 9 hospitals in Denmark.

93 randomized, double-blind, placebo-controlled multicenter trial conducted between February 2007 and Fe

94 S: The EDEN study, a randomized, open-label, multicenter trial conducted from January 2, 2008, throug

95 andomized, double-blind, placebo-controlled, multicenter trial conducted from January 2, 2008, throug

96 NTS: Randomized, noninferiority, open-label, multicenter trial conducted from May 2010 through March

97 andomized, double-blind, placebo-controlled, multicenter trial conducted in 7 medical intensive care

98 In a multicenter trial conducted in the tertiary care setting

99 , significantly more often (p < 0.0001) than multicenter trials conducted by ad hoc groups (n = 89; m

100 Data from three randomized phase III multicenter trials conducted by the Cancer and Leukemia

101 n aged 16-23 years in a phase 2, open-label, multicenter trial, conducted from 2008 to 2011 by the Ad

102 phase 3 trial, this randomized, controlled, multicenter trial demonstrated an additional reduction i

103 Our multicenter trial demonstrated safety and efficacy of tr

104 The results from this multicenter trial demonstrated that the treatment of inf

105 cular outflow tract conduits in 2010 after a multicenter trial demonstrating improvements in conduit

106 SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and sa

107 This study represents the first multicenter trial designed to evaluate an imaging approa

108 section and stoma in a randomized controlled multicenter trial, DILALA.

109 ave evaluated the Bonta criteria in a larger multicenter trial encompassing 4 academic institutions.

110 ided the basis for the phase III randomized, multicenter trial ENDEAVOR.

111 Materials and Methods This prospective multicenter trial enrolled 296 carriers of the BRCA muta

112 randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18-25 year

113 The HF-ACTION trial was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients

114 ND PARTICIPANTS: A double-blind, randomized, multicenter trial (enrollment October 30, 2014, to June

115 This multicenter trial establishes a GBEF lower limit of norm

116 This randomized phase II multicenter trial evaluated cabozantinib compared with s

117 This prospective phase II multicenter trial evaluated the efficacy and safety of a

118 This multicenter trial evaluated whether lopinavir/ritonavir

119 e prospectively enrolled in an international multicenter trial evaluating (18)F(-) PET/CT, (18)F-FDG

120 ollected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment

121 eport the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of

122 There have been no prospective, multicenter trials evaluating this technology.

123 significance of iron deficiency, randomized multicenter trials exploring the use of oral iron supple

124 :1 parallel, randomized, placebo-controlled, multicenter trial for 6 weeks, with an optional 6-week o

125 This largest prospective multicenter trial for adult patients with Burkitt lympho

126 ND PARTICIPANTS: A randomized, double-blind, multicenter trial from January 2016 to May 14, 2018 (las

127 Materials and Methods This prospective multicenter trial (from 2012-2016) recruited participant

128 competing for the same patient population as multicenter trials funded by the NIH.

129 ition, in a double-blind, placebo-controlled multicenter trial, galectin-9 levels were measured in th

130 on by all of the major pediatric liver tumor multicenter trial groups.

131 To date, no prospective multicenter trial has evaluated the diagnostic accuracy

132 the past year, the results of several large multicenter trials have been published, clearing the way

133 Multiple randomized, multicenter trials have established the role of the impl

134 Multicenter trials have shown echocardiographic techniqu

135 Imaging Network Cancer Research Group A6702 multicenter trial helped confirm the potential of diffus

136 Finally, two investigator-initiated multicenter trials highlighted doxycycline and dapsone a

137 andomized, double-blind, placebo-controlled, multicenter trials (identical confirmatory trials were c

138 cerbated COPD), a randomized, noninferiority multicenter trial in 5 Swiss teaching hospitals, enrolli

139 This was a phase 2 randomized, double-blind, multicenter trial in adults >=40 years old with treated

140 conducted a blinded, randomized, controlled, multicenter trial in children undergoing HSCT to determi

141 A PET, a secondary endpoint of a prospective multicenter trial in men with biochemical recurrence of

142 phase 2, randomized, parallel-group, blinded multicenter trial in patients with New York Heart Associ

143 ethods We evaluated IMMU-132 in a single-arm multicenter trial in patients with pretreated metastatic

144 uated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory m

145 In a multicenter trial in Spain, we randomly assigned partici

146 andomized, double-blind, placebo-controlled, multicenter trial in Switzerland between 2005 and 2012.

147 We conducted a randomized controlled, multicenter trial in the Netherlands, enrolling patients

148 The DECREASE-HF Trial is a multicenter trial in which 306 patients with New York He

149 We performed a prospective noninferiority multicenter trial in which 343 consecutive individuals w

150 We performed an open, multicenter trial in which infants with a birth weight o

151 We performed a multicenter trial in which patients 18 to 80 years of ag

152 We conducted a multicenter trial in which patients with sepsis-associat

153 We performed a multicenter trial in which women with a singleton fetus

154 A randomized multicenter trial included 212 kidney patients transplan

155 0-Detector Row Computed Tomography (CORE320) multicenter trial included 92 patients (mean age, 63.1 y

156 This prospective, nonrandomized, multicenter trial included adult patients with a standar

157 This prospectively designed, multicenter trial included all adult patients undergoing

158 This randomized (1:1), controlled, multicenter trial included subjects with DME (center poi

159 Ongoing multicenter trials including the Clinical Trials in Orga

160 s were prospectively enrolled as part of the multicenter trial Inflammation and the Host Response to

161 Z0010 was a prospective multicenter trial initiated in 1999 by the American Coll

162 This phase III randomized multicenter trial investigated the benefit of adding ED

163 ients pooled from two successive prospective multicenter trials investigating MKI in chemorefractory

164 TIENTS: Post hoc observational analysis of a multicenter trial involving 20,330 patients (age >/=50 y

165 he Dual Antiplatelet Therapy (DAPT) Study, a multicenter trial involving 220 US and international cli

166 We conducted a double-blind, multicenter trial involving 3020 patients with recent sy

167 andomized, double-blind, placebo-controlled, multicenter trial involving 586 outpatient participants

168 le-blind, placebo-controlled, parallel-group multicenter trial involving 663 US outpatient participan

169 was a prospective, double-blind, controlled, multicenter trial involving hospitalized adult patients

170 We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epith

171 repeatability of (18)F-FLT PET as part of a multicenter trial involving patients with high-grade gli

172 In this multicenter trial involving treatment-naive patients wit

173 We performed an open, international, multicenter trial involving women at 14 weeks 0 days to

174 We performed a multicenter trial involving women without symptoms of st

175 This post hoc study of 3 large multicenter trials involving 2- to 5-year-old children c

176 There is a need for multicenter trials involving defined patient populations

177 andomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute

178 early termination of the trial, and a larger multicenter trial is needed to evaluate the potential be

179 A larger multicenter trial is under way.

180 A large, adequately powered, multicenter trial is warranted to address these findings

181 More evidence from prospective multicenter trials is needed to confirm this.

182 In this prospective multicenter trial, MR severity was assessed in 103 patie

183 ouble-blind, randomized, placebo-controlled, multicenter trial (NCT00481767), healthy African girls a

184 In this double-blind, multicenter trial (NCT01700192) 1482 subjects (aged >/=1

185 In a multicenter trial, non-ST elevation acute coronary syndr

186 In this double-blind parallel-group multicenter trial of 186 patients with Alzheimer's disea

187 inal transit was validated using data from a multicenter trial of 320 segmental colectomy patients.

188 andomized, double-blind, placebo-controlled, multicenter trial of 789 patients with chronic HFpEF and

189 e outcome measures, using data from a large, multicenter trial of abatacept in lupus nephritis, to ga

190 In this prospective multicenter trial of chest pain patients without known C

191 This was a multicenter trial of children with ALL enrolled 4-12 mon

192 nciclovir or ganciclovir in an international multicenter trial of CMV disease treatment (the VICTOR s

193 lant recipients enrolled in an international multicenter trial of CMV disease treatment (the VICTOR s

194 In the Multicenter Trial of Cryotherapy for Retinopathy of Prem

195 : TAAA I, II, III) enrolled in a prospective multicenter trial of f/b-EVAR.

196 erm findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously

197 In this large, multicenter trial of kidney transplant recipients, we sh

198 ormance of various cardiac MR sequences in a multicenter trial of patients implanted with an MR-condi

199 ACT-1 is a prospective multicenter trial of patients who have standard surgical

200 We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosph

201 We conducted a randomized, double-blind, multicenter trial of RIV4 (45 mug of recombinant hemaggl

202 Interim data from our ongoing prospective multicenter trial of sentinel node (SN) biopsy indicate

203 A prospective, randomized, controlled, multicenter trial of the efficacy, safety, and tolerabil

204 ipants at 12 U.S. centers participating in a multicenter trial of treatment for acute traumatic brain

205 vated the initiation of a placebo-controlled multicenter trial of Triplex in HCT patients.

206 al, 125 patients were randomly assigned in a multicenter trial of vaccination series.

207 ER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppur

208 mprove overall survival compared with recent multicenter trials of biochemotherapy or chemotherapy.

209 d individual patient data from 13 randomized multicenter trials of induction and maintenance regimens

210 Data were combined from 3 prospective multicenter trials of patients referred for TPVR.

211 Further multicenter trials of this intervention are warranted.

212 Although multicentered trials of lactoferrin use in preterm infan

213 ysis was performed as part of a prospective, multicenter trial on (18)F-FCH or (68)Ga-PSMA PET, mpMR,

214 With the emergence of large multicenter trials over the past 20 years, the numbers o

215 clinical trials (P < .001), and by 5.2% for multicenter trials (P < .001).

216 Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to on

217 andomized, double-blind, placebo-controlled, multicenter trial, patients with >=1 SVGs were randomly

218 In this prospective, randomized controlled multicenter trial, patients with primary or recurrent in

219 In this 6-month randomized, multicenter trial, patients with type 1 diabetes were as

220 bo-controlled, double-blind, parallel-group, multicenter trial performed in 26 intensive care units i

221 Materials and Methods In this prospective multicenter trial, PET/CT and clinical data were reviewe

222 ) reduced mortality from septic shock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed

223 This multicenter trial provides data regarding the associatio

224 This prospective randomized multicenter trial provides evidence that clinical outcom

225 We conducted a prospective, multicenter trial, randomly assigning 190 patients who w

226 for aortic strain and PWV measurements in a multicenter trial setting using standardized MRI protoco

227 Our phase II multicenter trial showed that the R-GCVP regimen is an a

228 This multicenter trial showed that trimodality therapy with n

229 This randomized multicenter trial shows that prophylactic application of

230 Our large, multicenter trial shows that the gentamicin-collagen spo

231 idualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into

232 Methods CATCH was a randomized, multicenter trial that investigated tinzaparin 175 IU/kg

233 nd Late Loss Optimization) is a prospective, multicenter trial that randomized 182 patients with lesi

234 ified randomized trials, 4 were high-quality multicenter trials that involved a total of 17 133 patie

235 In a randomized, double-blind, multicenter trial, the efficacy and safety of prophylact

236 pective, controlled, randomized, stratified, multicenter trial to assess intravitreal bevacizumab mon

237 We conducted a phase II, multicenter trial to assess the efficacy and safety of b

238 rking Group Recovery Study was a prospective multicenter trial to assess the incidence of myocardial

239 andomized, placebo-controlled, double-blind, multicenter trial to assess the safety and efficacy of t

240 andomized, double-blind, placebo-controlled, multicenter trial to assess the safety, immunogenicity,

241 phylococcus aureus (MRSA) collected during a multicenter trial to determine if three negative culture

242 We conducted a double-blind, randomized multicenter trial to determine whether the addition of m

243 IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety,

244 opharmaceutical for Myocardial Imaging) is a multicenter trial to evaluate the accuracy, outcomes, an

245 (1) PANCREOX was a phase III multicenter trial to evaluate the benefit of FU and oxal

246 tcomes, we conducted a phase 2, prospective, multicenter trial to test the efficacy of the addition o

247 nce in Dialysis trial, a 6-month randomized, multicenter trial to test whether a simple, personalized

248 t steps in clinical development will require multicenter trials to establish adoptive immunotherapy a

249 wed combined data from 3 ongoing prospective multicenter trials to evaluate the experience with IE am

250 It will be necessary to design large multicenter trials to overcome the expected improvements

251 a reliable pharmacodynamic biomarker for ALS multicenter trials, TSPO radioligands have some challeng

252 andomized, double-blind, placebo-controlled, multicenter trial using a 2x2 factorial design in which

253 olled in a double-blind, placebo-controlled, multicenter trial using GRAZAX(R) during 2 years.

254 Samples were collected in a prospective, multicenter trial validating a gene expression classifie

255 le-blind, placebo-controlled, parallel-group multicenter trial was conducted in 406 adult patients wi

256 placebo-controlled, parallel-group, 24-week, multicenter trial was conducted to evaluate the efficacy

257 A phase II multicenter trial was conducted to evaluate the efficacy

258 This phase 3, double-masked, multicenter trial was designed to randomize 368 patients

259 ation is safe and efficacious, a randomized, multicenter trial was performed in 12 pediatric kidney t

260 A secondary analysis of a randomized multicenter trial was performed in order to determine th

261 This prospective randomized multicenter trial was performed to assess the potential

262 A phase 2 multicenter trial was performed to evaluate single-agent

263 on, a phase I-II, open-label, nonrandomized, multicenter trial was therefore designed using (99m)Tc-s

264 The purpose of this prospective multicenter trial was to study LAMPOON with transseptal

265 A phase II, multicenter trial was undertaken to assess the immunogen

266 MetaPlus study, a randomized, double-blind, multicenter trial, was conducted from February 2010 thro

267 e DIABOLO study, a randomized, double-blind, multicenter trial, was conducted from October 2011 throu

268 In this multicenter trial we established the clinical performanc

269 andomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infect

270 In a randomized, noninferiority, multicenter trial, we assigned 400 adults in stable cond

271 , double-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyr

272 In this multicenter trial, we enrolled 240 patients at high risk

273 In this 3-year open-label, multicenter trial, we evaluated 708 patients who had sub

274 In this phase 2 multicenter trial, we evaluated the activity of bortezom

275 In this double-blind, multicenter trial, we evaluated the efficacy and safety

276 In this phase 2 multicenter trial, we evaluated the efficacy of the comb

277 In this multicenter trial, we randomly assigned 131 patients who

278 In a multicenter trial, we randomly assigned 270 critically i

279 In this multicenter trial, we randomly assigned 552 patients who

280 In this randomized, prospective, open-label, multicenter trial, we randomly assigned 600 patients wit

281 In this multicenter trial, we randomly assigned 706 patients who

282 In an open-label, controlled, multicenter trial, we randomly assigned 708 patients wit

283 In this double-blind, multicenter trial, we randomly assigned 750 women, in a

284 In a double-blind, multicenter trial, we randomly assigned adult patients w

285 In this multicenter trial, we randomly assigned infants born at

286 In this multicenter trial, we randomly assigned nontunneled cent

287 In this multicenter trial, we randomly assigned patients 40 to 7

288 In this multicenter trial, we randomly assigned transplant recip

289 blished clinical randomized assessor-blinded multicenter trial were analyzed.

290 years old who participated in a prospective multicenter trial were divided into a training set (n =

291 5, 54.9% of all clinical trials and 55.6% of multicenter trials were NIH funded.

292 nitial 24 Month Outcomes) was a prospective, multicenter trial which enrolled 240 patients with singl

293 This study included patients enrolled in 3 multicenter trials, who received a leadless cardiac pace

294 randomized, placebo-controlled, double-blind multicenter trial will be performed for which 980 patien

295 he embedding of quantitative CT (QCT) into a multicenter trial with a variety of scanner makes and mo

296 We designed and implemented a multicenter trial with an adaptive, two-stage, bias-adju

297 In this open-label, multicenter trial with crossover design, we randomly ass

298 uble-blind, double-dummy, active-controlled, multicenter trial with the objective of evaluating the s

299 Multicenter trials with larger sample sizes are necessar

300 tudy provides a strong rationale for further multicenter trials with sufficient power to identify dif